CD45BE-HSPC + CART-45 Cells
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Rozpoznany chłoniak B-komórkowy (różne rodzaje DLBCL, chłoniak mieszkowy, chłoniak ziarnisty, chłoniak strefy brzegowej)
- •Rozpoznany chłoniak T-komórkowy
- •Choroba, która nie reaguje lub powróciła po dotychczasowym leczeniu
- •Wcześniejsze leczenie co najmniej 2 liniami terapii
- •Nieskuteczność lub brak możliwości otrzymania komercyjnej terapii CAR-T
- •Wyrażona świadoma zgoda pacjenta na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Pennsylvania
Philadelphia, United States
Trial contact
Abramson Cancer Center Clinical Trials Service
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.